Identifying illnesses at an early stage often means treatment can begin sooner, boosting the chances of recovery and reducing the impact on quality of life. This is particularly important for conditions like cancer, where late diagnosis can significantly limit treatment options and survival rates.
A new Australian-developed blood test is making headlines worldwide—for good reason. This innovative test could be a game-changer in the fight against ovarian cancer, a disease that has long been known as the ‘silent killer’ due to its lack of early symptoms and devastatingly late diagnoses.
Unveiled at the prestigious American Society of Clinical Oncology conference in the United States, the INNOVIQ EXO-OC™ Test, created in a Melbourne laboratory, is hailed as a potential lifesaver for thousands of women.
The test’s early trial results are nothing short of remarkable. Scientists reported that it can detect ovarian cancer in its earliest—and most treatable—stages.
Ovarian cancer is notoriously difficult to catch early. Unlike other cancers, it rarely causes symptoms until it has already spread, making early detection challenging.
As a result, the statistics are sobering: one Australian woman dies from ovarian cancer every eight hours, and the five-year survival rate hovers around just 30 per cent.
Most women are diagnosed only after the disease has advanced, when treatment options are limited and outcomes are poor.
But the new blood test could change all that. According to Professor Greg Rice from the University of Queensland, who played a key role in developing the test, the latest trials showed that the EXO-OC™ test correctly identified all early-stage ovarian cancers.
‘This will be a world-first,’ said Dr Leearne Hinch, chief executive officer of the company behind the test. ‘Our test will enable many women’s lives to be saved globally.’
For women like Emily Jol, the impact of such a test is deeply personal. At just 21, Emily was told that an ovarian cyst found during a routine ultrasound was ‘completely normal’.
She was reassured that there was nothing to worry about—it was just part of being a woman, she was told. But Emily trusted her instincts and kept pushing for answers.
Six months later, after surgery, she finally received the diagnosis: ovarian cancer. Thankfully, it was caught before it had spread, and Emily considers herself ‘really, really lucky’. But she’s the exception, not the rule.
The INNOVIQ EXO-OC™ Test is a simple blood test, making it far less invasive than current diagnostic methods, which often involve surgery or complex imaging.
The test works by detecting tiny particles called exosomes, which are released by cancer cells into the bloodstream, even in the earliest stages of the disease. The test can spot ovarian cancer before symptoms appear by analysing these exosomes.
The implications are enormous if the test also continues to perform in larger trials. Experts believe that early detection could push the five-year survival rate for ovarian cancer from 30 per cent to over 90 per cent.
‘We’re very proud that this is Australian science,’ Dr Hinch said.
The test is still undergoing further evaluation. However, if all goes well, it could receive regulatory approval in the United States within two to three years and become available globally soon after.
The Ovarian Cancer Research Foundation partly funded the development of the INNOVIQ EXO-OC™ Test, which is a shining example of what can be achieved when research, innovation, and determination come together.
While the test isn’t available just yet, its progress is being watched closely by the medical community—and by women everywhere who have been waiting for a breakthrough in ovarian cancer detection.
Have you or someone you know been affected by ovarian cancer? What are your thoughts on this breakthrough? Would you take a blood test for early cancer detection if available? We’d love to hear your stories, thoughts, and questions in the comments below.
Also read: Don’t ignore the signs: 3 in 4 Australians with high blood pressure are in the dark
